Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362817 · ClinicalTrials.gov registry record · Phase 1
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00362817 is a Phase 1 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 17 participants.
The verdict
NCT00362817, a Phase 1 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from cancer in other parts of the body, compared to patients who have already been treated with radiation. Survival, causes of death, recurrence of disease in the central nervous system, toxicity, and quality of life will all be measured as secondary objective in this study.
Interventions
- DRUG carboplatin
- DRUG temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-10 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00362817
The ClinicalTrials.gov registry entry for NCT00362817 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT00362817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00362817 about?
NCT00362817 is a clinical study titled "Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases". Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from cancer in other parts of the body, compared to patients who have already be...
What is the current status of trial NCT00362817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2004-10. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00362817?
The interventions under investigation include: carboplatin (DRUG), temozolomide (DRUG).
Who is sponsoring clinical trial NCT00362817?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.